Trial · NCT00000143
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
NCT00000143, Phase 3, Completed, Johns Hopkins Bloomberg School of Public Health; results first posted 2016-03-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT). Trials, record NCT00000143. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00000143
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
- NCT number
- NCT00000143
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 61 participants, actual
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Ganciclovir implant and oral ganciclovir, Cidofovir intravenous
- First posted
- 1999-09-24
- Last updated
- 2016-03-14
- Results first posted
- 2016-03-14
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Survival | 3 years |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Survival | 3 years | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Survival | Ganciclovir Implant and Oral Ganciclovir | 31 | participants | ||
| Survival | Cidofovir IV (Intravenous) | 30 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ganciclovir Implant and Oral Ganciclovir | 31 | |
| Overall Study | STARTED | Cidofovir IV (Intravenous) | 30 | |
| Overall Study | COMPLETED | Ganciclovir Implant and Oral Ganciclovir | 31 | |
| Overall Study | COMPLETED | Cidofovir IV (Intravenous) | 30 | |
| Overall Study | NOT COMPLETED | Ganciclovir Implant and Oral Ganciclovir | 0 | |
| Overall Study | NOT COMPLETED | Cidofovir IV (Intravenous) | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ganciclovir Implant and Oral Ganciclovir | ||
| Total, all-cause mortality | Cidofovir IV (Intravenous) | ||
| Total, other adverse events | Ganciclovir Implant and Oral Ganciclovir | 0 | 31 |
| Total, other adverse events | Cidofovir IV (Intravenous) | 0 | 30 |
| Total, serious adverse events | Ganciclovir Implant and Oral Ganciclovir | 0 | 31 |
| Total, serious adverse events | Cidofovir IV (Intravenous) | 0 | 30 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Ganciclovir Implant and Oral Ganciclovir vs Cidofovir IV (Intravenous): Survival | Trial comparisons |
| Ganciclovir Implant and Oral Ganciclovir vs Cidofovir IV (Intravenous): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00000143
GET https://conductscience.org/api/trials/v1/NCT00000143/registered